Virazole (ribavirin for inhalation solution, USP) is the inhaled formulation of ribavirin and is FDA‑approved for treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV) (Virazole product information). The policy focuses specifically on the inhaled (Virazole) formulation delivered via the SPAG‑2 aerosol generator and references the manufacturer dosing recommendation of a 20 mg/mL solution in the SPAG‑2 reservoir with continuous aerosol administration for 12–18 hours/day for 3–7 days, yielding an average aerosol concentration of about 190 mcg/L for a 12‑hour delivery period (Virazole prescribing information and CPB dosing note).

Beyond the approved RSV indication, the policy reviews evidence for use of ribavirin across multiple other infectious and non‑infectious conditions. The literature cited in the CPB describes variable and often limited evidence supporting off‑label uses, including oral and systemic ribavirin data for hepatitis E (HEV) (case reports, small series and retrospective studies showing viral clearance in some solid‑organ transplant patients but with dose‑limiting anemia), and older studies or case series for hepatitis C (HCV) and other viral infections (background HEV and HCV reports).

For respiratory and emerging viral indications the CPB summarizes mixed and inconclusive data: inhaled or systemic ribavirin has been used for RSV and parainfluenza in immunocompromised patients with limited observational evidence (case series and small, uncontrolled reports) suggesting possible benefit if given early but without high‑quality randomized data; inhaled ribavirin aerosol formulations have been explored for coronaviruses including COVID‑19 in early‑phase and small clinical trials, yielding preliminary pharmacokinetic/safety data and limited efficacy signals that require further controlled study (phase I/II trials and open‑label reports).

Ribavirin has also been studied or reported in a range of other contexts (viral hemorrhagic fevers such as Lassa, Crimean‑Congo, Ebola/Marburg; Rift Valley and hantaan viruses; oncology indications including glioblastoma, thyroid and oral cancers; and veterinary/experimental settings such as foot‑and‑mouth disease). The CPB notes that evidence quality varies widely across these areas — from guideline recommendations and systematic reviews raising questions about benefit in some hemorrhagic fevers to in‑vitro and preclinical anti‑tumor activity — and concludes that effectiveness for most of these non‑RSV indications has not been established.

Consistent with the variable evidence base, the policy designates inhaled ribavirin as medically necessary for a limited set of serious viral infections when selection criteria are met (RSV in high‑risk or immunosuppressed patients; specified viral hemorrhagic fevers; Rift Valley and Hantaan infections) and labels other uses as experimental and investigational (not covered) because effectiveness has not been established (examples listed include acute myeloid leukemia, COVID‑19, hepatitis E, parainfluenza in some settings, glioblastoma, thyroid and oral cancers).